Biomarkers to identify patients that will respond to treatment and treating such patients
作者： Simon Steward Jones , Min Yang
DOI:
关键词:
摘要: The invention relates to methods for using biomarkers identify cancer patients that will or are likely respond treatment. Specifically, the use of one more three association studies types, gene mutations, expression levels in order treatment with a histone deacetylase (HDAC) inhibitor, alone combination another may, optionally, further include treating such patient an HDAC
lens.org 参考文章(28)
David Lee Tamang, Simon S. Jones, Min Yang, Combinations of histone deacetylase inhibitors and either Her2 inhibitors or PI3K inhibitors ,(2014)
Matthew Blair Jarpe, Simon S. Jones, Specific regulation of cytokine levels by hdac6 inhibitors ,(2011)
Joseph J. Buggy, Sriram Balasubramanian, Methods for determining cancer resistance to histone deacetylase inhibitors ,(2008)
Christopher C. Benz, Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby ,(2002)
Steven Norman Quayle, Simon Stewart Jones, Combinations of histone deacetylase inhibitors and immunomodulatory drugs ,(2014)
Ralph Mazitschek, James Elliott Bradner, Nan Yu, Guoxiang Huang, Walter Ogier, Dejian Xie, John H. Van Duzer, Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof ,(2011)
Sascha Hovelmann, Monika Raab, Elke Martin, Alexander B. Maurer, Bernd Hentsch, Using Inhibitors of Histone Deacetylases for the Suppression Therapy of Inherited Disease Predisposing Conditions ,(2005)
John H. Van Duzer, Ralph Mazitschek, Selective hdac3 inhibitors ,(2014)
Stephen J. Haggarty, Teru Hideshima, Ralph Mazitschek, James Elliott Bradner, Jared Shaw, Kenneth C. Anderson, Stuart L. Schreiber, Nicholas Paul Kwiatkowski, Edward Franklin Greenberg, Treatment of protein degradation disorders ,(2006)
Steven Norman Quayle, Simon Stewart Jones, HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma ,(2014)